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EDITORIAL

Hemodialysis Catheter Device Protection:
Damned if We Do; Patients Are Damned
if We Don’t

I

n this issue of Advances in Chronic Kidney Disease, Guest
Editor Mohanram Narayanan, MD, reinvigorates the
prior theme of infections in kidney patients. Infections
are frequent in nephrology patients and often deadly.
Each of Dr. Narayanan’s authors pointedly contributes
his/her wisdom to the infection theme. So, before reading
more, please read each article carefully to enhance your
practical working knowledge on behalf of your patients.
As a member of the Michigan Chapter of the American
College of Physicians, we recently had a robust discussion
about pay for performance. Part of the discussion was
about reimbursement for documentation of what the
physician educated and intended the patient to do rather
than what the patient outcomes are. We believe this to be
fair because there must be some ownership of one’s medical care and outcomes. Given the emphasis on patient
centeredness and autonomy, health-care providers cannot
go home with patients and “force” the issue.
As a corollary, should nephrologists be pilloried for their
inability to achieve the laudable goals of the Fistula First
Breakthrough Initiative? Better yet, can we achieve the
more well-considered goal of the Catheter Last initiative?
Probably not, if patients cannot successfully undergo arteriovenous (AV) ﬁstula constructions or AV graft placements. Also, some patients, for personal, social, or
environmental reasons, simply reject the idea of either
AV ﬁstula/graft surgery or peritoneal dialysis. The common denominator, for better or worse, is the hemodialysis
(HD) catheter, the most frequently used in-hospital
vascular access for acute kidney injury patients who
require renal replacement therapy.
In the absence of renal recovery, the non-tunneled catheter is exchanged for a tunneled catheter, the consequence
of which is the acquired disorder, “catheter perpetuation
syndrome.” This disorder is only cured after much
cajoling by the nephrologist physician–care provider
following episodic catheter-related bloodstream infections or central line-associated bloodstream infections

(CLABSIs). Remarkably, catheter perpetuation usually involves the patient/decider who declares that catheters are
not painful and also that the CLABSI is the fault of the
provider. These arguments, although ﬂawed, are clearly
lucid to the patient (end-user). Thus, nephrology has a
tautological problem of getting the world rid of CLABSIs
that it has created. This is akin to the prosperity of industrialization with the penalty of climate change. As we
should reduce carbon-based emissions to prevent global
warming, we must decrease the frequency and prevalence
of HD catheters and the complication of CLABSIs.
Nearly all the solutions have been imposed, and
nephrology has implemented them at the provider level,
ie, interdisciplinary chronic kidney disease clinics, patient
education regarding AV ﬁstula and graft surgery, inpatient rapid-start peritoneal dialysis for patients with acute
kidney injury (AKI) requiring renal replacement therapy,
and so forth. However, one solution with proven value
has not been universally adopted. To apply the term “universally” is bloviation because this solution has hardly
been adopted despite the fact that this answer is well researched, well published, well known, and consistently
appears in nephrology examinations. Somehow, this
sounds like promulgating handwashing to prevent infection. Admittedly, we have snatched victory from the jaws
of defeat.
Most recent United States Renal Data Survey data published in 2017 indicate that the per-patient per-year cost to
care for an in-center HD patient is $88,750.1 A substantial
proportion of this cost is related to dialysis access-related
care and its associated complications.2 Despite aggressive
measures since the Fistula First Breakthrough Initiative
began over a decade ago, 36% of AV ﬁstulas still fail to
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ever mature, and 80% of patients with incident end-stage
renal disease who are on HD still begin treatment with a
tunneled HD catheter. At 1 year, catheter prevalence remains at approximately 20%.1 When compared with patients on HD with AV access, patients receiving dialysis
with a tunneled central venous catheter (CVC) have
higher rates of access-related infection, sepsis, and mortality. The ﬁnancial costs of CLABSI have been determined to
approximate $45,000 per event.3 The patient-centered
costs are greater, and the long-term consequences are
clearly more severe. Given the known concerns of lifethreatening patient outcomes, long-term morbidity, and
costs to the health-care system associated with CLABSIs
(hospitalizations, repeated access procedures and patient
fatigue, endocarditis and septic arthritis, hospital readmissions, and loss of reimbursement), can we do more
for our patients?
The Centers for Disease Control published a group of
“dialysis safety core interventions” in 2016 to help reduce
CLABSIs. These standards have been applied throughout
the country and have had a powerful impact on CVC
complication rates in short-term studies.4 These interventions include staff training, meticulous hand hygiene and
surveillance, and use of best practices with vascular access
care, chlorhexidine skin preparation, and “scrub the hub”
catheter disinfection.5 Application of antimicrobial ointment to the catheter exit site during dressing changes
has also been shown to reduce CLABSI rates in patients
with CVCs and is now part of the Centers for Disease
Control’s core interventions. Nevertheless, CLABSI rates
continue to be reported anywhere between 1.1–5.5 episodes per 1000 catheter-days.6
Antimicrobial locks (AMLs) are solutions instilled into
the catheter lumens of CVCs for the duration of time between dialysis treatments (48 to 72 hours) (Fig 1). Each
contains a high concentration of an antimicrobial agent
and has been used with the intention of eradicating bacteria that colonize the bioﬁlm present in the internal lumens
of all CVCs. The properties of an ideal AML solution
should include adequate concentrations of antimicrobial
agent to prevent CLABSIs without producing systemic
toxicity, vascular thrombosis, or resistant bacteria.
Antimicrobial agents used in AML are generally categorized as either antibiotic or non-antibiotic and typically
contain some form of anticoagulant (heparin, citrate, or
tissue plasminogen activator). Differing antibiotics have
been used in AML (eg, vancomycin, cefazolin, ceftazidime, ciproﬂoxacin), but gentamicin has been the most
studied antibiotic, either with heparin or citrate. One of
the ﬁrst randomized, controlled trials (RCT) indicating
the clinical beneﬁt of AML was conducted by al Hweish
and colleagues in 2007.7 This group conducted an RCT
of 63 subjects using either vancomycin plus gentamicin
and heparin vs a standard heparin catheter lock solution.
The intervention arm showed a signiﬁcant reduction in
CLABSIs of 0.65 events per 1000 dialysis sessions
compared with 4.88 events per 1000 dialysis sessions in
the control arm (P , 0.001).7 Another RCT performed in
2009 by Zhang consisted of 140 subjects with over
34,000 catheter-days using a gentamicin-heparin AML

vs standard heparin.8 The intervention group showed statistically signiﬁcant reductions in CLABSIs (0.06 per 1000
catheter-days) despite the fact that the control group had a
very low rate of events as well (0.67 events per 1000 catheter-days).8 As questions have been raised regarding the
possible negative impact—rather than just neutral—of
heparin as a catheter locking solution, Moran conducted
an RCT using gentamicin with 4% sodium citrate vs standard heparin locking solution in 303 subjects totaling
more than 72,000 catheter-days.9 Again, core interventions led to a low incidence of CLABSIs in the control
arm (0.91 events per 1000 catheter-days), whereas the
gentamicin–4% citrate AML resulted in a signiﬁcant
reduction in CLABSIs (0.28 events per 1000 catheterdays).9
What about the risk of antibiotic resistance from longterm exposure to AML? A large, observational, retrospective study in 2010 (1410 patients with 142,000 catheterdays) was the ﬁrst study to support such concerns.
Although the intervention arm (gentamicin-heparin
AML) lowered the CLABSI rate effectively (decrease
from 17 to 0.83 events per 1000 catheter-days during the
4-year intervention), gentamicin resistance was noted
within 6 months.10 To further address this question, a prospective, multicenter, observational cohort study by
Moore was published in 2014.11 This has been the largest
study of an AML to date (155,518 catheter-days). The
gentamicin–4% citrate solution was compared with the
standard heparin lock solution in 555 patients on HD
over a 4-year period. The CLABSI rate in the antibiotic
lock period (0.45 per 1000 catheter-days) was 73% lower
than that in the heparin period (1.68 per 1000 catheterdays; P ¼ 0.001). Equally important, AML therapy was
associated with a survival advantage (hazard ratio, 0.32;
95% conﬁdence interval, 0.14 to 0.75, after multivariate
adjustment) and a reduction in the rate of gentamicinresistant organisms (0.40 per 1000 person-years to 0.22
per 1000 person-years) in the AML period.11
Nonantibiotic AMLs such as solutions containing taurolidine, trisodium citrate, or ethanol have also been studied
and show signiﬁcant promise. Although helping to hopefully eliminate any potential risk for the emergence of
antibiotic resistance, there are concerns regarding the potential for toxicity, as well as damage to catheter integrity.
The use of trisodium citrate at concentrations of 30% or
higher to avoid catheter thrombosis has shown mixed results in several studies. These have primarily been used as
an adjunct to antibiotic catheter locks.12 The antimicrobial
taurolidine has been reported in several studies, with citrate showing signiﬁcant reductions in catheter-related
bloodstream infections. However, there has been concern
regarding the increased incidence of catheter thrombosis,
leading to the use of heparin and urokinase in the most
recent RCT.13 Ethanol is another antimicrobial sterilant,
with signiﬁcant data reported in the pediatric literature
for prophylaxis and catheter salvage of CLABSIs in children with long-term peripherally inserted central catheter
lines due to severe malnutrition from short gut syndrome.
Its prophylactic use in patients with end-stage renal disease with tunneled CVC has been studied over the last
Adv Chronic Kidney Dis. 2019;26(1):1-4
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several years and summarized with a recent meta-analysis
of 7 RCTs consisting of 2575 patients with 3375 catheterdays, indicating signiﬁcantly decreased risk of CLABSI
(relative risk, 0.54; 95% conﬁdence interval, 0.38 to 0.78;
P ¼ 0.001).14 Of note, not all patients included in this
study were using CVCs for dialysis. There has also been
a concern regarding the use of ethanol and systemic
toxicity (nausea and transient dizziness) and damage to
catheter integrity despite more recent data from our group
contradicting this concern.
In a recent Cochrane database meta-analysis of 39
studies and 4216 patients, the use of AMLs (antibiotic
antimicrobial and combined antibiotic plus nonantibiotic
lock solutions) decreased the incidence of CLABSIs
compared with control lock solutions, usually heparin.
The nonantibiotic lock solutions did not signiﬁcantly
reduce CLABSIs when compared with the standard heparin lock solutions.15
Finally, the Federal Drug Administration has more
recently approved a nonantibiotic, antimicrobial CVC
closure device consisting of CVC caps containing an internal rod coated with chlorhexidine that dissolves in a standard heparin lock solution upon contact. Chlorhexidine is
a well-established nonantibiotic antimicrobial. It is
currently used as part of the standard scrub the hub technique when accessing HD catheters and has shown superiority to povidone iodine solutions in terms of
diminishing infection rates. Two prospective multicenter
RCTs have evaluated these catheter caps (ClearGuardÔ).
Collectively, there were dramatic and sustained reductions in CLABSI rates with no signiﬁcant side effects.
Cost has been the only deterrent to widespread use, ie,
the cost is borne by the dialysis provider.16,17
Are AMLs cost-effective? Data regarding the costeffectiveness of antibiotic catheter locks have been addressed and appear to support beneﬁt. A recently published retrospective audit on CLABSI rates and
associated ﬁnancial implications from a single center in
New Zealand supports this tenet. Goh and colleagues reported their experience during 3 phases of catheter locking solutions over a 5-year span from 2010 to 2015,
during which time there was a 12.5-month absence of
gentamicin-heparin AML (supplier had withdrawn the
product from the market) that had been their standard
of care for all HD tunneled CVCs for the previous
24 months from 2010 to 2012.18 The authors used heparin
locks (1000 units/mL) because of absence of AML only to
resume AML practice with gentamicin-citrate in 2014.
Over 144,000 catheter-days were reviewed with a total
of 89 CLABSIs during this 5-year span. When compared
to the heparin-only lock (1.42), both gentamicin-heparin
and gentamicin-citrate AMLs had reduced CLABSI rates
of 0.66 and 0.16 per 1000 catheter-days, respectively.
Application of the same standard of care—including the
scrub the hub technique—was the same throughout the
entire period. Inpatient costs (in New Zealand dollars)
as a result of CLABSI events were $27,792 per 1000
catheter-days for heparin-only locks, $10,608 per 1000
catheter-days for gentamicin-heparin AML, and $1898
per 1000 catheter-days for gentamicin-citrate AML.18

Figure 1. Antimicrobial lock solutions are proven prophylaxis for central line-associated bloodstream infections.

Who uses tunneled dialysis catheters? Typically, these are
“crash starts” of patients with end-stage renal disease and
those with acute kidney injury, those with failed and
maturing vascular access, and those who have simply
refused vascular access for a multiplicity of reasons. Data
from the Dialysis Outcomes and Practice Patterns Study
(DOPPS) indicate that although patients with catheters
and AV grafts have a higher number of access complications and higher mortality, the actual access complications
may not explain this increased mortality rate, raising the
question of patient baseline statistics (social economic
status, medical comorbidities) as likely factors behind the
ability to achieve not only successful AV access but also
being the main driver behind mortality. Is the possession
of a tunneled dialysis catheter simply an independent
marker of health status? Most of our clinical experiences
would indicate this being very likely true.19
Have our well-intentioned efforts to improve outcomes
of patients on HD and societal costs led to an overestimation of the beneﬁts of AV ﬁstulas and ironically contributed
to increased catheter prevalence? Does this represent the
unintended consequence of confusing association (of catheters with mortality) with causality? Changing the
perspective from a “Fistula First” initiative to a “Catheter
Last” initiative did not remediate the problem at its core.
At the end of the day, we are tasked with making our patients safer with the most well-thought-out methods available. In the world of dialysis, this means decreasing
infection rates while also fulﬁlling our responsibility of
antibiotic stewardship to prevent the development of antibiotic resistance. Based on present-day data and over a
decade of AML experience, a strong and logical argument
can be made that it is actually costing health care more to
not use and support the use of AMLs. Truly, regarding HD
catheter protection devices, we are damned if we do, and
patients are damned if we don’t.
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